{"entity":"eli-lilly","id":"ent_eli-lilly","name":"Eli Lilly and Company","wikidata":"Q632240","page":"https://asof.is/record/eli-lilly","summary":"Eli Lilly and Company is an American pharmaceutical company, headquartered in Indianapolis. It reported revenue of $45.04B for the period ended December 31, 2024.","title":"Eli Lilly and Company: revenue $45.04B","key_facts":[{"label":"Chair","value":"David Ricks","claim":"clm_86AF538802D3"},{"label":"CFO","value":"Lucas Montarce","claim":"clm_868742F69055"},{"label":"Headquarters","value":"Indianapolis","claim":"clm_8346D7F2C725"},{"label":"Revenue","value":"$45.04B","recorded":"45,042,700,000 United States dollar","note":"to 2024-12-31","claim":"clm_282E1F71B318"},{"label":"Ticker","value":"LLY · NYSE","claim":"clm_E590A7180C31"}],"faq":[{"question":"Where is Eli Lilly and Company headquartered?","answer":"Indianapolis."},{"question":"What is Eli Lilly and Company's revenue?","answer":"$45.04B for the period ended December 31, 2024."}],"as_of":"2025-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"chair","page":"https://asof.is/record/eli-lilly/chair","md":"https://asof.is/record/eli-lilly/chair.md","json":"https://asof.is/v1/entities/eli-lilly/chair"},{"predicate":"cfo","page":"https://asof.is/record/eli-lilly/cfo","md":"https://asof.is/record/eli-lilly/cfo.md","json":"https://asof.is/v1/entities/eli-lilly/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/eli-lilly/headquarters","md":"https://asof.is/record/eli-lilly/headquarters.md","json":"https://asof.is/v1/entities/eli-lilly/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/eli-lilly/revenue","md":"https://asof.is/record/eli-lilly/revenue.md","json":"https://asof.is/v1/entities/eli-lilly/revenue"},{"predicate":"net_income","page":"https://asof.is/record/eli-lilly/net_income","md":"https://asof.is/record/eli-lilly/net_income.md","json":"https://asof.is/v1/entities/eli-lilly/net_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/eli-lilly/quarterly_revenue","md":"https://asof.is/record/eli-lilly/quarterly_revenue.md","json":"https://asof.is/v1/entities/eli-lilly/quarterly_revenue"}],"products":[],"coverage":{"entity":"eli-lilly","name":"Eli Lilly and Company","kind":"organization","sources":[{"source":"wikidata","item":"Q632240","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":59478,"ticker":"LLY","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":511,"open":20,"retracted":0,"first":"1994-07-27","predicates":{"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":71,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":75,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":46,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"research_and_development":{"claims":16,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":3,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"chair":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":511,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_599C7D287C29","predicate":"cash_and_equivalents","value":"9,791,900,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 9,791,900,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_599C7D287C29, https://asof.is/claim/clm_599C7D287C29, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_599C7D287C29","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AEB07A485FC9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_868742F69055","predicate":"cfo","value":"Lucas Montarce","valid_from":"2024-01-01","valid_to":null,"published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cfo: Lucas Montarce\", as of 2024-01-01. Claim clm_868742F69055, https://asof.is/claim/clm_868742F69055, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm.","url":"https://asof.is/claim/clm_868742F69055","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-12T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Lucas Montarce 48 Executive Vice President and Chief Financial Officer (since 2024).","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm"}},{"id":"clm_86AF538802D3","predicate":"chair","value":"David Ricks","valid_from":"2017-01-01","valid_to":null,"published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company chair: David Ricks\", as of 2017-01-01. Claim clm_86AF538802D3, https://asof.is/claim/clm_86AF538802D3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm.","url":"https://asof.is/claim/clm_86AF538802D3","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-12T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"David Ricks 58 Chair, President, and Chief Executive Officer (CEO) (since 2017).","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm"}},{"id":"clm_91F284A9D7C8","predicate":"cik","value":"0000059478","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cik: 0000059478\", undated. Claim clm_91F284A9D7C8, https://asof.is/claim/clm_91F284A9D7C8, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_91F284A9D7C8","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4809DE70CF2A","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company fiscal year end: 12-31\", undated. Claim clm_4809DE70CF2A, https://asof.is/claim/clm_4809DE70CF2A, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_4809DE70CF2A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_8346D7F2C725","predicate":"headquarters","value":"Indianapolis","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company headquarters: Indianapolis\", undated. Claim clm_8346D7F2C725, https://asof.is/claim/clm_8346D7F2C725, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_8346D7F2C725","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/","tier":"secondary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q632240","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B1897509C990","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company listed on: NYSE\", undated. Claim clm_B1897509C990, https://asof.is/claim/clm_B1897509C990, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_B1897509C990","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2BC21A73296C","predicate":"net_income","value":"10,590,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 10,590,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_2BC21A73296C, https://asof.is/claim/clm_2BC21A73296C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_2BC21A73296C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DBEC55E24C06","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-19T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-19"}},{"id":"clm_74B5C29B477B","predicate":"quarterly_net_income","value":"5,582,500,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 5,582,500,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_74B5C29B477B, https://asof.is/claim/clm_74B5C29B477B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_74B5C29B477B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_063460475B4C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_A1B2A03455D9","predicate":"quarterly_research_and_development","value":"2,356,500,000 United States dollar","valid_from":"2023-06-30","valid_to":null,"published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 2,356,500,000 United States dollar\", as of 2023-06-30. Claim clm_A1B2A03455D9, https://asof.is/claim/clm_A1B2A03455D9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_A1B2A03455D9","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2023, filed 2023-08-08"}},{"id":"clm_D3881089FBD6","predicate":"quarterly_revenue","value":"17,600,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 17,600,800,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_D3881089FBD6, https://asof.is/claim/clm_D3881089FBD6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_D3881089FBD6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DF742A5515B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_95F26A6CA639","predicate":"registrant_name","value":"ELI LILLY & Co","valid_from":"2019-10-25","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company registrant name: ELI LILLY & Co\", as of 2019-10-25. Claim clm_95F26A6CA639, https://asof.is/claim/clm_95F26A6CA639, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_95F26A6CA639","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B291C97A9E9C","predicate":"research_and_development","value":"7,190,800,000 United States dollar","valid_from":"2022-12-31","valid_to":null,"published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 7,190,800,000 United States dollar\", as of 2022-12-31. Claim clm_B291C97A9E9C, https://asof.is/claim/clm_B291C97A9E9C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_B291C97A9E9C","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_282E1F71B318","predicate":"revenue","value":"45,042,700,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 45,042,700,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_282E1F71B318, https://asof.is/claim/clm_282E1F71B318, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_282E1F71B318","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C4636B99C62B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-19T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-19"}},{"id":"clm_3242C5557E98","predicate":"shares_outstanding","value":"945,383,757 shares","valid_from":"2025-10-27","valid_to":"2026-02-09","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 945,383,757 shares\", as of 2025-10-27 (until 2026-02-09). Claim clm_3242C5557E98, https://asof.is/claim/clm_3242C5557E98, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_3242C5557E98","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5A4FA78D8054","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_2509C2A3A267","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_2509C2A3A267, https://asof.is/claim/clm_2509C2A3A267, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_2509C2A3A267","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A5EA16045303","predicate":"state_of_incorporation","value":"IN","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company state of incorporation: IN\", undated. Claim clm_A5EA16045303, https://asof.is/claim/clm_A5EA16045303, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_A5EA16045303","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E590A7180C31","predicate":"ticker","value":"LLY","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company ticker: LLY\", undated. Claim clm_E590A7180C31, https://asof.is/claim/clm_E590A7180C31, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_E590A7180C31","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_C3E87E59336F","predicate":"total_assets","value":"114,935,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 114,935,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_C3E87E59336F, https://asof.is/claim/clm_C3E87E59336F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_C3E87E59336F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C278ED944402","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_AA3E6D040F0E","predicate":"total_equity","value":"23,793,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 23,793,300,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_AA3E6D040F0E, https://asof.is/claim/clm_AA3E6D040F0E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_AA3E6D040F0E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6628DA8282A8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-30"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date"}}}